Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Research & Development (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Research & Development data on record, last reported at $122.0 million in Q1 2025.

  • For Q1 2025, Research & Development changed N/A year-over-year to $122.0 million; the TTM value through Mar 2025 reached $453.0 million, changed N/A, while the annual FY2024 figure was $448.0 million, 31.76% up from the prior year.
  • Research & Development reached $122.0 million in Q1 2025 per RCUS's latest filing, down from $123.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $123.0 million in Q3 2024 and bottomed at $50.6 million in Q4 2021.
  • Average Research & Development over 5 years is $83.0 million, with a median of $80.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 186.87% in 2021, then decreased 8.11% in 2022.
  • A 5-year view of Research & Development shows it stood at $50.6 million in 2021, then skyrocketed by 58.14% to $80.0 million in 2022, then rose by 16.25% to $93.0 million in 2023, then soared by 32.26% to $123.0 million in 2024, then fell by 0.81% to $122.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $122.0 million in Q1 2025, $123.0 million in Q3 2024, and $115.0 million in Q2 2024.